Efficacy and ototoxicity of different cyclodextrins in Niemann-Pick C disease

Annals of Clinical and Translational Neurology

Volumn 3, Issue 5, 2016, Pages 366-380

  Davidson, Cristin D ^a   Fishman, Yonatan I ^a   Puskás, István ^b   Szemán, Julianna ^b   Sohajda, Tamás ^b   Mccauliff, Leslie A ^c   Sikora, Jakub ^a,d   Storch, Judith ^c   Vanier, Marie T ^e   Szente, Lajos ^b   Walkley, Steven U ^a   Dobrenis, Kostantin ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CycloLab Cyclodextrin Research & Development Laboratory Ltd   (Hungary)

^c RUTGERS UNIVERSITY   (United States)

^d General Teaching Hospital and 1st Medical Faculty of Charles University   (Czech Republic)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL ALPHA CYCLODEXTRIN; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2 HYDROXYPROPYL GAMMA CYCLODEXTRIN; ALPHA CYCLODEXTRIN SULFOBUTYL ETHER; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CHOLESTEROL; CYCLODEXTRIN; GAMMA CYCLODEXTRIN DERIVATIVE; GAMMA CYCLODEXTRIN SULFOBUTYL ETHER; GANGLIOSIDE GM2; GLUCOSYLCERAMIDE; GLYCOLIPID; LACTOSYLCERAMIDE; OLEIC ACID; OXYSTEROL; SPHINGOSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; CHEMICAL INTERACTION; CLINICAL TRIAL (TOPIC); COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SOLUBILITY; ELECTROPHYSIOLOGY; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEOCORTEX; NIEMANN PICK DISEASE; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY;

EID: 85012968875     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.306     Document Type: Article

References (60)

1. Vanier MT. Complex lipid trafficking in Niemann-Pick disease type C. J Inherit Metab Dis 2015;38:187-199.
2. Infante RE, Wang ML, Radhakrishnan A, et al. NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc Natl Acad Sci USA 2008;105:15287-15292.
3. Rosenbaum AI, Maxfield FR. Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J Neurochem 2011;116:789-795.
4. Davidson CD, Ali NF, Micsenyi MC, et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE 2009;4:e6951.
5. Liu B, Li H, Repa JJ, et al. Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res 2008;3:663-669.
6. Liu B, Turley SD, Burns DK, et al. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc Natl Acad Sci USA 2009;106:2377-2382.
7. Liu B, Ramirez CM, Miller AM, et al. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. J Lipid Res 2010;51:933-944.
8. Chen FW, Li C, Ioannou YA. Cyclodextrin induces calcium-dependent lysosomal exocytosis. PLoS ONE 2010;5:e15054.
9. Song W, Wang F, Lotfi P, et al. 2-Hydroxypropyl-beta-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy. J Biol Chem 2014;289:10211-10222.
10. Ramirez CM, Liu B, Aqul A, et al. Quantitative role of LAL, NPC2, and NPC1 in lysosomal cholesterol processing defined by genetic and pharmacological manipulations. J Lipid Res 2011;52:688-698.
11. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008;36:30-42.
12. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997;86:147-162.
13. Tanaka Y, Yamada Y, Ishitsuka Y, et al. Efficacy of 2-Hydroxypropyl-beta-cyclodextrin in Niemann-Pick disease type C model mice and its pharmacokinetic analysis in a patient with the disease. Biol Pharm Bull 2015;38:844-851.
14. Soga M, Ishitsuka Y, Hamasaki M, et al. HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells. Stem Cells 2015;33:1075-1088.
15. Ward S, O'Donnell P, Fernandez S, et al. 2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease. Pediatr Res 2010;68:52-56.
16. Crumling MA, Liu L, Thomas PV, et al. Hearing loss and hair cell death in mice given the cholesterol-chelating agent hydroxypropyl-beta-cyclodextrin. PLoS ONE 2012;7:e53280.
17. Vite CH, Bagel JH, Swain GP, et al. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. Sci Transl Med 2015;7:276ra26.
18. Davies JP, Chen FW, Ioannou YA. Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science 2000;290:2295-2298.
19. Praggastis M, Tortelli B, Zhang J, et al. A murine Niemann-Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele. J Neurosci 2015;35:8091-8106.
20. Lloyd-Evans E, Morgan AJ, He X, et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med 2008;14:1247-1255.
21. Chevallier J, Chamoun Z, Jiang G, et al. Lysobisphosphatidic acid controls endosomal cholesterol levels. J Biol Chem 2008;283:27871-27880.
22. Kolter T, Sandhoff K. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu Rev Cell Dev Biol 2005;21:81-103.
23. Heverin M, Meaney S, Lutjohann D, et al. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 2005;46:1047-1052.
24. Björkhem I, Lutjohann D, Diczfalusy U, et al. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 1998;39:1594-1600.
25. Björkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 2006;260:493-508.
26. McCauliff LA, Xu Z, Storch J. Sterol transfer between cyclodextrin and membranes: similar but not identical mechanism to NPC2-mediated cholesterol transfer. Biochemistry 2011;50:7341-7349.
27. Loftus SK, Morris JA, Carstea ED, et al. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 1997;277:232-235.
28. McGlynn R, Dobrenis K, Walkley SU. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 2004;480:415-426.
29. Fujita N, Suzuki K, Vanier MT, et al. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet 1996;5:711-725.
30. Sybilska D, Zukowski J, Bojarski J. Resolution of mephenytoin and some chiral barbiturates into enantiomers by reversed phase high performance liquid chromatography via β-Cyclodextrin inclusion complexes. J Liq Chromatogr 1986;9(2-3):591-606.
31. Wallingford RA, Ewing AG. Capillary electrophoresis.Adv Chromatogr 1989;29:1-76.
32. Rundlett KL, Armstrong DW. Examination of the origin, variation, and proper use of expressions for the estimation of association constants by capillary electrophoresis. J Chromatogr A 1996;721:173-186.
33. Higuchi T, Connors KA. Phase solubility techniques. Pp. 117-212 Advances in analytical chemistry and instrumentation. New York, NY: Wiley Interscience, 1965.
34. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 2002;110:905-911.
35. Wang MD, Kiss RS, Franklin V, et al. Different cellular traffic of LDL-cholesterol and acetylated LDL-cholesterol leads to distinct reverse cholesterol transport pathways. J Lipid Res 2007;48:633-645.
36. Taylor AM, Liu B, Mari Y, et al. Cyclodextrin mediates rapid changes in lipid balance in Npc1-/- mice without carrying cholesterol through the bloodstream. J Lipid Res 2012;53:2331-2342.
37. Tanaka Y, Ishitsuka Y, Yamada Y, et al. Influence of Npc1 genotype on the toxicity of hydroxypropyl-beta-cyclodextrin, a potentially therapeutic agent, in Niemann-Pick Type C disease models. Mol Genet Metab Rep 2014;1:19-30.
38. Leroy-Lechat F, Wouessidjewe D, Andreux JP, et al. Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int J Pharm 1994;101(1-2):97-103.
39. Schonfelder U, Radestock A, Elsner P, et al. Cyclodextrin-induced apoptosis in human keratinocytes is caspase-8 dependent and accompanied by mitochondrial cytochrome c release. Exp Dermatol 2006;15:883-890.
40. Salem LB, Bosquillon C, Dailey LA, et al. Sparing methylation of beta-cyclodextrin mitigates cytotoxicity and permeability induction in respiratory epithelial cell layers in vitro. J. Contr Release 2009;136:110-116.
41. Rajewski RA, Traiger G, Bresnahan J, et al. Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives. J Pharm Sci 1995;84:927-932.
42. Kiss T, Fenyvesi F, Bacskay I, et al. Evaluation of the cytotoxicity of beta-cyclodextrin derivatives: evidence for the role of cholesterol extraction. Eur J Pharm Sci 2010;40:376-380.
43. Juhn SK, Hunter BA, Odland RM. Blood-labyrinth barrier and fluid dynamics of the inner ear. Int Tinnitus J 2001;7:78-83.
44. Vecsernyes M, Fenyvesi F, Bacskay I, et al. Cyclodextrins, blood-brain barrier, and treatment of neurological diseases. Arch Med Res 2014;45:711-729.
45. Monnaert V, Tilloy S, Bricout H, et al. Behavior of alpha-, beta-, and gamma-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier. J Pharmacol Exp Ther 2004;310:745-751.
46. Rosenbaum AI, Zhang G, Warren JD, et al. Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc Natl Acad Sci USA 2010;107:5477-5482.
47. Abi-Mosleh L, Infante RE, Radhakrishnan A, et al. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells. Proc Natl Acad Sci USA 2009;106:19316-19321.
48. Yancey PG, Rodrigueza WV, Kilsdonk EP, et al. Cellular cholesterol efflux mediated by cyclodextrins. Demonstration Of kinetic pools and mechanism of efflux. J Biol Chem 1996;271:16026-16034.
49. Steck TL, Ye J, Lange Y. Probing red cell membrane cholesterol movement with cyclodextrin. Biophys J 2002;83:2118-2125.
50. Lopez CA, de Vries AH, Marrink SJ. Computational microscopy of cyclodextrin mediated cholesterol extraction from lipid model membranes. Sci Rep 2013;3:2071.
51. Besenicar MP, Bavdek A, Kladnik A, et al. Kinetics of cholesterol extraction from lipid membranes by methyl-beta-cyclodextrin-a surface plasmon resonance approach. Biochim Biophys Acta 2008;1778:175-184.
52. Malathi K, Higaki K, Tinkelenberg AH, et al. Mutagenesis of the putative sterol-sensing domain of yeast Niemann Pick C-related protein reveals a primordial role in subcellular sphingolipid distribution. J Cell Biol 2004;164:547-556.
53. Zervas M, Dobrenis K, Walkley SU. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol 2001;60:49-64.
54. Gondre-Lewis MC, McGlynn R, Walkley SU. Cholesterol accumulation in NPC1-deficient neurons is ganglioside dependent. Curr Biol 2003;13:1324-1329.
55. Zhou S, Davidson C, McGlynn R, et al. Endosomal/lysosomal processing of gangliosides affects neuronal cholesterol sequestration in Niemann-Pick disease type C. Am J Pathol 2011;179:890-902.
56. Mitsumori R, Kato T, Hatanaka K. g-Cyclodextrin increases hydrolysis of gangliosides by sialidase from Arthrobacter ureafaciens: hydrolysis of gangliosides. Int J Carbohydrate Chem 2008;2009:1-4.
57. Anheuser S, Breiden B, Schwarzmann G, et al. Membrane lipids regulate ganglioside GM2 catabolism and GM2 activator protein activity. J Lipid Res 2015;56:1747-1761.
58. Shafaati M, Olin M, Bavner A, et al. Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo. J Intern Med 2011;270:377-387.
59. Karuna R, Holleboom AG, Motazacker MM, et al. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis 2011;214:448-455.
60. Meske V, Erz J, Priesnitz T, et al. The autophagic defect in Niemann-Pick disease type C neurons differs from somatic cells and reduces neuronal viability. Neurobiol Dis 2014;64:88-97.